SLNO
Soleno Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$53.01
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +153.2%
- EBIT
- +142.1%
- EPS
- +142.4%
- Free cash flow
- +217.9%
- Operating cash flow
- +218.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +116.3%
- EBIT
- +108.0%
- Net income
- +111.9%
- EPS
- +109.4%
- Free cash flow
- +167.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026